Skip to main content
SpringerLink
Log in

Problems in the Evaluation of Theoretical Risks for Humans to Become Infected with BSE-Contaminated Bovine-Derived Pharmaceutical Products

  • Chapter
Bovine Spongiform Encephalopathy

Part of the book series: Serono Symposia USA Norwell, Massachusetts ((SERONOSYMP))

  • 92 Accesses

Abstract

The safety of bovine-derived pharmaceutical products with respect to bovine spongiform encephalopathy (BSE) has been the topic of several scientific meetings in the last few years (1–13), and although a consensus on the factors that must be considered for their evaluations has been reached, it is still difficult for manufacturers and authorities to defermine an objective estimate of the potential level of BSE contamination for each drug or to allocate precise figures to each risk factor. This chapter weighs each risk factor in order to facilitate uniform application by competent authorities. However, this chapter does not give a magic formula with which to decide whether a product should be kept on, or removed from, the market. The decision regarding the usefulness of a medicinal product should take into consideration not only the estimated potential risk but also, and most important, its inherent benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bovine Spongiform Encephalopathies (BSE) Roundtable. Bethesda, MD: National Institutes of Health, 1989.

    Google Scholar 

  2. BSE and related agents: risk factors of biological products. An informal consultation, 1990, Annecy, France.

    Google Scholar 

  3. International meeting. Virological aspects of the safety of biological products, 1990, London. In: International Association of Biological Standardization, ed. Developments in biological standards, vol 75. Basel: Karger, 1991.

    Google Scholar 

  4. BSE Seminar, 1990, Brussels (Belgium). In: Bradley R, Savey M, Marchant B, eds. Sub-acute spongiform encephalopathies. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1991.

    Google Scholar 

  5. Mad cow disease (BSE)—danger by food and drugs? 1991, Bonn, Germany.

    Google Scholar 

  6. Roundtable/workshop on public health issues associated with bovine spongiform encephalopathy. Bethesda, MD: National Institutes of Health, 1991.

    Google Scholar 

  7. Transmissible spongiform encephalopathies: their impact on the safety of medicinal products. Lagen, Germany: Paul-Ehrlich-Institut, 1991.

    Google Scholar 

  8. Committee for Proprietary Medicinal Products. Ad hoc working party on biotechnology/pharmacy on safety of medicines: EEC regulatory document. Note for guidance. Guidelines for minimizing the risk of transmission of agents causing spongiform encephalopathies via medicinal products, 1991, Brussels, Belgium. Biologicals 1992;20:155–158.

    Article  Google Scholar 

  9. WHO. Consultation on public health issues, related to animal and human spongiform encephalopathies, 1991, Geneva: WHO Bull 1992;70:183–190.

    Google Scholar 

  10. International Meeting on Transmissible Spongiform Encephalopathies. Impact on animal and human health, 1992, Heidelberg, Germany. In: International Association of Biological Standardization, ed. Developments in biological standards, vol 80. Basel: Karger, 1993.

    Google Scholar 

  11. Bovine spongiform encephalopathy—where are we now? European Commission Meeting of the Scientific Veterinary Committee with Scientific Experts, 1993, Brussels, Belgium. In: Bradley R, Marchant B, eds. Transmissible spongiform encephalopathies. Brussels: Working Document for the European Commission, Ref.: F.II.3-JC/0003, 1994.

    Google Scholar 

  12. Symposium, “Transmissible spongiform encephalopathies,” 1993, Berlin.

    Google Scholar 

  13. VI International Workshop on Bovine Spongiform Encephalopathy “The BSE Dilemma,” 1995, Williamsburg, VA.

    Google Scholar 

  14. Savey M, Coudert M, Jobert JL, Fontaine JJ, Belli P. Bovine spongiform encephalopathy (BSE) risk assessment and surveillance in France. In: Bradley R, Marchant B, eds. Transmissible spongiform encephalopathies. Brussels: Working Document for the European Commission, Ref.: F.II.3-JC/0003, 1994:57–67.

    Google Scholar 

  15. Guarda F, Castiglione F, Agrimi U, Cardone F, Caracappa S, Pocchiari M. Bovine spongiform encephalopathy in Italy. Eur J Vet Pathol 1995;1:71–72.

    Google Scholar 

  16. Fraser H, Bruce ME, Chree A, McConnell I, Wells GAH. Transmission of bovine spongiform and scrapie to mice. J Gen Virol 1992;73:1891–1897.

    Article  PubMed  Google Scholar 

  17. Fraser H, Foster JD. Transmission to mice, sheep and goats and bioassay of bovine tissues. In: Bradley R, Marchant B, eds. Transmissible spongiform encephalopathies. Brussels: Working Document for the European Commission, Ref.: F.II.3-JC/0003, 1994:145–159.

    Google Scholar 

  18. Hadlow WJ, Kennedy RC, Race RE, Eklund CM. Virologic and neurohistologic findings in dairy goats affected with natural scrapie. Vet Pathol 1980; 17:187–199.

    Article  PubMed  CAS  Google Scholar 

  19. Hadlow WJ, Kennedy RC, Race RE. Natural infection of Suffolk sheep with scrapie virus. J Infect Dis 1982;146:657–664.

    Article  PubMed  CAS  Google Scholar 

  20. Taylor DM, Dickinson AG, Fraser H, Robertson PA, Salcinski PR, Lowry PJ. Preparation of growth hormone free from contamination with unconventional viruses. Lancet 1985;2:260–262.

    Article  PubMed  CAS  Google Scholar 

  21. Pocchiari M, Macchi G, Peano S, Conz A. Can potential hazard of Creutzfeldt-Jakob disease infectivity be reduced in the production of human growth hormone? Inactivation experiments with the 263K strain of scrapie. Arch Virol 1988;98:131–135.

    Article  PubMed  CAS  Google Scholar 

  22. Diringer H, Braig HR. Infectivity of unconventional viruses in dura mater. Lancet 1989;1:439–440.

    Article  PubMed  CAS  Google Scholar 

  23. Dormont D, Deslys JP, Bouissin F, et al. Inactivation of unconventional slow viruses and HIV in human extractive biological products used in human therapy. Biotechnol Plasma Proteins 1989;175:355–364.

    CAS  Google Scholar 

  24. Pocchiari M, Peano S, Conz A, et al. Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination. Horm Res 1991;35:161–166.

    Article  PubMed  CAS  Google Scholar 

  25. Di Martino A, Safar J, Ceroni M, Gibbs CJ Jr. Purification of non-infectious ganglioside preparations from scrapie-infected brain tissue. Arch Virol 1992;124:111–121.

    Article  PubMed  Google Scholar 

  26. Di Martino A, Safar J, Gibbs CJ Jr. The consistent use of organic solvents for purification of phospholipids from brain tissue effectively removes scrapie infectivity. Biologicals 1994;22:221–225.

    Article  PubMed  CAS  Google Scholar 

  27. Pocchiari M. Methodological aspects of the validation of purification procedures of human/animal derived products to remove unconventional slow viruses. Dev Biol Stand 1991;75:87–95.

    PubMed  CAS  Google Scholar 

  28. Fraser H. The pathology of natural and experimental scrapie. In: Kimberlin RH, ed. Slow virus disease of animals and man. Amsterdam: North-Holland, 1976:267–305.

    Google Scholar 

  29. Brown P. Iatrogenic Creutzfeldt-Jakob disease. Aust NZ J Med 1990;20:633–635.

    Article  CAS  Google Scholar 

  30. Reed LJ, Muench H. A simple method of estimating 50% endpoints. Am J Hyg 1938;27:493–497.

    Google Scholar 

  31. Rohwer RG. Virus-like sensitivity of the scrapie agent to heat inactivation. Science 1984;223:600–602.

    Article  PubMed  CAS  Google Scholar 

  32. Rohwer RG. Scrapie infectious agent is virus-like in size and susceptibility to inactivation. Nature 1984;308:658–662.

    Article  PubMed  CAS  Google Scholar 

  33. Kimberlin RH, Walker CA. Pathogenesis of experimental scrapie. In: Bock G, Marsh J, eds. Novel infectious agents and the central nervous system. Ciba Foundation Symposium 135. Chichester, UK: John Wiley & Sons, 1988:37–54.

    Google Scholar 

  34. Pocchiari M, Salvatore M, Ladogana A, et al. Experimental drug treatment of scrapie: a pathogenetic basis for rationale therapeutics. Eur J Epidemiol 1991;7:556–561.

    Article  PubMed  CAS  Google Scholar 

  35. Prusiner SB, Cochran SP, Alpers MP. Transmission of scrapie in hamsters. J Infect Dis 1985;152:971–978.

    Article  PubMed  CAS  Google Scholar 

  36. Kimberlin RH, Walker CA. Pathogenesis of scrapie in mice after intragastric infection. Virus Res 1989;12:213–220.

    Article  PubMed  CAS  Google Scholar 

  37. Barlow RM, Middleton DJ. Dietary transmission of bovine spongiform encephalopathy to mice. Vet Rec 1990;126:111–112.

    PubMed  CAS  Google Scholar 

  38. Taylor DM, Fraser H, McConnell I, et al. Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie. Arch Virol 1994; 139:313–326.

    Article  PubMed  CAS  Google Scholar 

  39. Brown P, Cathala F, Rauberats RF, Gajdusek DC, Castaigne P. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987;37:895–904.

    PubMed  CAS  Google Scholar 

  40. Alperovitch A, Brown P, Weber T, Pocchiari M, Hofman A, Will R. Incidence of Creutzfeldt-Jakob disease in Europe in 1993. Lancet 1994;343:918.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Maurizio Pocchiari
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Laboratory of Central Nervous System Studies Basic Neurosciences Program Division of Intramural Research, National Institute of Neurological Disorders and Stroke National Institutes of Health, Bethesda, MD, 20892-4122, USA

    Clarence J. Gibbs Jr. Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Pocchiari, M. (1996). Problems in the Evaluation of Theoretical Risks for Humans to Become Infected with BSE-Contaminated Bovine-Derived Pharmaceutical Products. In: Gibbs, C.J. (eds) Bovine Spongiform Encephalopathy. Serono Symposia USA Norwell, Massachusetts. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2406-8_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-2406-8_28

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7527-5

  • Online ISBN: 978-1-4612-2406-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation